Linking Hong Kong, Unlocking a New Future for Cell Therapy in Qianhai – Grand Opening of Shenzhen-Hong Kong Cell Valley

Launch Ceremony ▼

(Shenzhen, May 20, 2025) – Today, Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. officially opened its doors at the Qianhai Shenzhen-Hong Kong Youth Dream Factory in Shenzhen. This milestone marks the formal launch of the project and signals a new chapter in deep collaboration between Shenzhen and Hong Kong in the fields of cell therapy and the biopharmaceutical industry.

The grand opening ceremony attracted a distinguished gathering of representatives from government, academia, and industry. Distinguished guests included Professor Jiang Yuyang, Deputy Director of the Shenzhen Municipal People's Congress Standing Committee and Chairman of the Shenzhen Association for Science and Technology; relevant leaders from the Qianhai Administration; Dr. Zheng Jinzhong, Chairman of the Hong Kong Greater China Cancer Foundation; Professor Yu Changhai, Chairman of the Hong Kong Society for Biotechnology; as well as experts, scholars, and corporate representatives from medical institutions and the biopharmaceutical sector.

In his opening address, Professor Shi Yuanyuan, Founder of Shenzhen-Hong Kong Cell Valley, stated that the company will be rooted in Qianhai, Shenzhen, while maintaining close synergy with Hong Kong. By fully integrating the advantages of both regions in scientific research, industrial capacity, and policy support, the company aims to build a one-stop service platform covering the entire value chain of cell and gene therapy. This platform will span medical services, innovative drug R&D, manufacturing, general wellness, and medical aesthetics/anti-aging. Leveraging the supportive policies of the Qianhai Free Trade Zone, Shenzhen-Hong Kong Cell Valley is committed to accelerating the clinical translation and industrial implementation of cutting-edge technologies.

Professor Yu Changhai, Chairman of the Hong Kong Society for Biotechnology, noted in his speech that the establishment of Shenzhen-Hong Kong Cell Valley is a paradigmatic example of complementary advantages and collaborative innovation between the two cities. He highlighted that Hong Kong possesses significant strengths in the internationalization of biotechnology, scientific research accumulation, and talent reserves, while Shenzhen continues to exert strong momentum in technological innovation, industrial incubation, and policy support. He affirmed that this partnership will inject new vitality into the biopharmaceutical industry of the Greater Bay Area.

Witnessed by the distinguished guests on site, Shenzhen-Hong Kong Cell Valley held a solemn opening ceremony, symbolizing the official commencement of its journey and the dawn of a new era in the industrialization of cell therapy.

Additionally, three strategic cooperation agreements were signed at the event:

1. Joint Venture with Academician Yan Xiyun’s Team (Chinese Academy of Sciences): Co-establishment of "Shenzhen Ecological Niche Cell Medicine Co., Ltd." to jointly develop a global first-in-class CD146-CLL1 dual-target cell therapy drug.

2. Strategic Partnership with the Hong Kong Greater China Cancer Foundation: Designation as a Charitable Partner of the Foundation to provide advanced cell therapy solutions for patients in Hong Kong and the Greater Bay Area.

3. Collaboration with Southern Medical University Shenzhen Hospital: Co-establishment of the "Institute for Cell Therapy Translation" to create an integrated innovation platform encompassing R&D, translation, and clinical application.

The opening of Shenzhen-Hong Kong Cell Valley is not only a significant milestone for the enterprise but also a new starting point for the deep integration of the biopharmaceutical industries in Shenzhen and Hong Kong. Looking ahead, Shenzhen-Hong Kong Cell Valley will continue to strengthen collaboration with global research institutions, universities, and industry partners. Focusing on breakthroughs in core key technologies, the company is dedicated to accelerating the realization of both clinical value and commercial value in cell therapy.

For more photos, please scan the QR code below.